Claritev Corporation CTEV
21.67 USD 0.00 (+0.00%)
At closeNov 5, 2026, 5:33 AM EST
21.99 +0.32 +1.48%
Pre-market · Nov 5, 5:33 AM ET
21.54 Day range 22.63
11.50 52-week range 73.68
- YTD
- -49.31%
- 1 year
- -65.53%
News
globenewswire.com Claritev Corporation Announces Participation in Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum MCLEAN, Va., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data, and insights company, today announced that members of its…
globenewswire.com Claritev Introduces Transparency-Based Pricing, Turning Complex Public Market Data into Actionable Reimbursement Intelligence MCLEAN, Va., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a healthcare technology, data, and insights company, today announced the launch of…
zacks.com Claritev Corporation (CTEV) Surges 5.2%: Is This an Indication of Further Gains? Claritev Corporation (CTEV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the…
defenseworld.net Claritev (NYSE:CTEV) SVP Sells $138,383.72 in Stock Claritev (NYSE: CTEV - Get Free Report) SVP Tiffani Misencik sold 5,812 shares of the stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $23.81, for a…
globenewswire.com Claritev Appoints Jennifer Main to its Board of Directors MCLEAN, Va., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data, and insights company, today announced that its Board of Directors…
globenewswire.com Claritev Corporation Announces Third Quarter 2026 Earnings Conference Call MCLEAN, Va., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a healthcare technology, data, and insights company focused on making healthcare more…
defenseworld.net Reviewing Claritev (NYSE:CTEV) and Schrodinger (NASDAQ:SDGR) Schrodinger (NASDAQ: SDGR - Get Free Report) and Claritev (NYSE: CTEV - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on…
seekingalpha.com Claritev: Revenue Growth Is Back, Cash Flow Is The Next Test Claritev is showing early signs of a turnaround, with revenue and bookings growth supporting a Buy rating and a $34 price target (+40% upside). CTEV's 2027 earnings growth is critical, as high…
defenseworld.net Claritev (NYSE:CTEV) CFO Douglas Michael Garis Sells 9,025 Shares Claritev (NYSE: CTEV - Get Free Report) CFO Douglas Garis sold 9,025 shares of the firm's stock in a transaction that occurred on Monday, September 21st. The stock was sold at an average price of…
benzinga.com Claritev Selected By General Dynamics Information Technology To Support The World Trade Center Health Program; Terms Not Disclosed The WTC Health Program is a limited federal health care program established under the James Zadroga 9/11 Health and Compensation Act of 2010 (Extended in 2015). It provides nationwide medical…
businesswire.com Claritev Selected by GDIT to Support CDC's World Trade Center Health Program MCLEAN, Va.--(BUSINESS WIRE)---- $CTEV #GDIT--Claritev Corporation (NYSE: CTEV), a healthcare technology, data, and insights company focused on making healthcare more affordable, transparent and fair…
defenseworld.net Claritev (NYSE:CTEV) Receives Consensus Rating of “Moderate Buy” from Brokerages Claritev (NYSE: CTEV - Get Free Report) has been assigned an average rating of "Moderate Buy" from the nine analysts that are presently covering the stock, MarketBeat.com reports. One analyst has…
gurufocus.com Claritev Corp (CTEV) Stock Down 5.5% but Still Overvalued -- GF Score: 63/100 On September 17, 2026, Claritev Corp (CTEV) shares fell 5.5%, bringing the current price to $31.73. The stock has experienced a significant decline, with a rang
businesswire.com Claritev Releases 2025 Corporate Responsibility Report MCLEAN, Va.--(BUSINESS WIRE)---- $CTEV #CommunityImpact--Claritev Corporation ("Claritev" or the "Company") (NYSE: CTEV), a healthcare technology, data, and insights company, today announced the…
seekingalpha.com Claritev Corporation (CTEV) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Claritev Corporation (CTEV) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
businesswire.com Claritev Appoints Ben Letham to its Board of Directors MCLEAN, Va.--(BUSINESS WIRE)---- $CTEV #BoardOfDirectors--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data, and insights company, today announced that its Board of…
businesswire.com Claritev Cares Helps Rural Patients Get Critical Care Closer to Home MCLEAN, Va.--(BUSINESS WIRE)---- $CTEV #ClaritevCares--Claritev Corporation (NYSE: CTEV), a healthcare technology, data, and insights company focused on making healthcare more affordable and…
businesswire.com Claritev Corporation Announces Participation in Upcoming Events MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a healthcare technology, data, and insights company, today announced that members of its management team…- benzinga.com Barclays Maintains Overweight on Claritev, Raises Price Target to $40 Barclays analyst Glen Santangelo maintains Claritev (NYSE:CTEV) with a Overweight and raises the price target from $28 to $40.
benzinga.com Claritev Expands Collaboration With Marpai To Launch Pre, Post- Payment Integrity Services To Health Plans Claritev Corporation (NYSE: CTEV), a healthcare technology, data, and insights company, today announced that Marpai, Inc. (OTCQX:MRAI) has expanded its relationship with Claritev to bring…
businesswire.com Marpai Expands Relationship with Claritev to Help Reduce Healthcare Costs for Employer Clients MCLEAN, Va.--(BUSINESS WIRE)---- $CTEV #ClaimsManagement--Claritev Corporation (NYSE: CTEV), a healthcare technology, data, and insights company, today announced that Marpai, Inc. (OTCQX: MRAI) has…- benzinga.com Wells Fargo Maintains Equal-Weight on Claritev, Raises Price Target to $30 Wells Fargo analyst Stan Berenshteyn maintains Claritev (NYSE:CTEV) with a Equal-Weight and raises the price target from $22 to $30.
benzinga.com Claritev Analysts Raise Their Forecasts Following Q2 Earnings Claritev Corp (NYSE:CTEV) on Friday reported better-than-expected second-quarter financial results and raised its FY26 sales guidance above estimates.
benzinga.com Claritev Analysts Raise Their Forecasts Following Q2 Earnings CTEV reported better-than-expected Q2 results and raised FY26 sales guidance. Analysts maintain Buy ratings with increased price targets.
benzinga.com Citigroup Maintains Buy on Claritev, Raises Price Target to $45 Citigroup analyst Daniel Grosslight maintains Claritev (NYSE:CTEV) with a Buy and raises the price target from $40 to $45.
benzinga.com Canaccord Genuity Maintains Buy on Claritev, Raises Price Target to $43 Canaccord Genuity analyst Richard Close maintains Claritev (NYSE:CTEV) with a Buy and raises the price target from $37 to $43.
marketbeat.com Claritev Q2 Earnings Call Highlights Claritev NYSE: CTEV reported second-quarter revenue growth, record bookings and higher cash flow, prompting the healthcare technology company to raise its full-year revenue, adjusted EBITDA and…
benzinga.com Claritev Raises FY2026 Sales Guidance from $985.000M-$1.000B to $1.000B-$1.020B vs $993.511M Est Claritev (NYSE:CTEV) raises FY2026 sales outlook from $985.000 million-$1.000 billion to $1.000 billion-$1.020 billion vs $993.511 million estimate.
benzinga.com Claritev Q2 EPS $(3.49) Beats $(4.21) Estimate, Sales $257.478M Beat $244.813M Estimate Claritev (NYSE:CTEV) reported quarterly losses of $(3.49) per share which beat the analyst consensus estimate of $(4.21) by 17.1 percent. This is a 8.4 percent increase over losses of $(3.81) per…- benzinga.com Canaccord Genuity Maintains Buy on Claritev, Raises Price Target to $37 Canaccord Genuity analyst Richard Close maintains Claritev (NYSE:CTEV) with a Buy and raises the price target from $32 to $37.
- benzinga.com Claritev Says DOJ Closes Antitrust Grand Jury Probe, Confirms Company Not Under Criminal Investigation As stated in the Form 8-K filed on May 18, 2026, in August 2024 Claritev Corporation (the "Company") received a confidential grand jury subpoena issued by the Antitrust Division of the Department of…
benzinga.com 7 Health Care Stocks With Whale Alerts In Today's Session 
benzinga.com Claritev Q1 2026 Earnings Call Transcript - benzinga.com Canaccord Genuity Initiates Coverage On Claritev with Buy Rating, Announces Price Target of $32 Canaccord Genuity analyst Richard Close initiates coverage on Claritev (NYSE:CTEV) with a Buy rating and announces Price Target of $32.
benzinga.com The High-Yield Stocks the Smart Money Is Buying Right Now Smart credit team Ares Mgmt bought discounted BDCs aggressively in Q1 2026. They're not guessing but expressing conviction in 17 positions.
benzinga.com Claritev Corp Says Received DOJ Grand Jury Subpoena In August 2024 For Health Insurance Investigation, Denies Being Identified As Target Following Reported Probe Allegations An article published on Thursday, May 14, 2026 alleges that "DOJ launches criminal antitrust probe into Claritev." In August of 2024, Claritev Corporation (the "Company") received a confidential…- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com Claritev Raises FY2026 Sales Guidance from $980.000M-$1.000B to $985.000M-$1.000B vs $989.607M Est Claritev (NYSE:CTEV) raises FY2026 sales outlook from $980.000 million-$1.000 billion to $985.000 million-$1.000 billion vs $989.607 million estimate.
benzinga.com Claritev Q1 EPS $(4.41) Misses $(3.85) Estimate, Sales $244.678M Beat $236.389M Estimate Claritev (NYSE:CTEV) reported quarterly losses of $(4.41) per share which missed the analyst consensus estimate of $(3.85) by 14.55 percent. This is a 0.68 percent decrease over losses of $(4.38) per…- benzinga.com Barclays Initiates Coverage On Claritev with Overweight Rating, Announces Price Target of $28 Barclays analyst Glen Santangelo initiates coverage on Claritev (NYSE:CTEV) with a Overweight rating and announces Price Target of $28.
- benzinga.com Wells Fargo Maintains Equal-Weight on Claritev, Lowers Price Target to $22 Wells Fargo analyst Stan Berenshteyn maintains Claritev (NYSE:CTEV) with a Equal-Weight and lowers the price target from $30 to $22.
benzinga.com Alpha Buying: Following the Insiders Into a Volatile Market - benzinga.com Citigroup Maintains Buy on Claritev, Lowers Price Target to $21 Citigroup analyst Daniel Grosslight maintains Claritev (NYSE:CTEV) with a Buy and lowers the price target from $63 to $21.
benzinga.com Nasdaq Gains Over 1%; Keurig Dr Pepper Earnings Top Views 
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session - benzinga.com Guggenheim Maintains Buy on Claritev, Lowers Price Target to $38 Guggenheim analyst Jason Cassorla maintains Claritev (NYSE:CTEV) with a Buy and lowers the price target from $43 to $38.
- benzinga.com Wells Fargo Maintains Equal-Weight on Claritev, Lowers Price Target to $30 Wells Fargo analyst Stan Berenshteyn maintains Claritev (NYSE:CTEV) with a Equal-Weight and lowers the price target from $33 to $30.
benzinga.com Claritev Q4 Earnings Summary & Key Takeaways - benzinga.com Claritev Q4 EPS $(4.88) Misses $(4.72) Estimate, Sales $246.554M Beat $241.025M Estimate Claritev (NYSE:CTEV) reported quarterly losses of $(4.88) per share which missed the analyst consensus estimate of $(4.72) by 3.39 percent. This is a 5.43 percent increase over losses of $(5.16) per…